Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
Status:
Unknown status
Trial end date:
2020-05-15
Target enrollment:
Participant gender:
Summary
Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. In most
cases, platelet count is negatively correlated with the severity of bleeding. Correcting low
platelets is the main measure to prevent bleeding in patients with ITP. Both rhTPO and
eltrombopag act on TPO receptors to increase platelets.Which one will have a better
short-term (2 weeks) effect to improve platelets is the purpose of the investigator's
research.
Phase:
Phase 4
Details
Lead Sponsor:
Wuhan Union Hospital, China
Collaborators:
The First Affiliated Hospital of Nanchang University The First People's Hospital of Yuhang District The Third Xiangya Hospital of Central South University Xiangyang Central Hospital